Erratum to: Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease. (Expert Opin Investig Drugs, (2015), 24, 2, (219-27), 10.1517/13543784.2015.963195);Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease

Expert Opinion on Investigational Drugs

Volumn 24, Issue 2, 2015, Pages 219-227

  Carta, Anna R ^a   Simuni, Tanya ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antidiabetic; Parkinson; Pioglitazone; PPAR ; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ANTIPARKINSON AGENT; DOPAMINE; NEUROPROTECTIVE AGENT;

AREA UNDER THE CURVE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SCREENING; HUMAN; IMMUNOCOMPETENT CELL; MAXIMUM PLASMA CONCENTRATION; MOTOR DYSFUNCTION; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIMATE; PROTEIN EXPRESSION; REVIEW; RODENT; STEADY STATE; SUBSTANTIA NIGRA; TIME TO MAXIMUM PLASMA CONCENTRATION; AGONISTS; ANIMAL; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; DOPAMINE; DRUG EVALUATION, PRECLINICAL; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 84921309888     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2016.1212573     Document Type: Erratum

References (95)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-35
2. Willis AW. Parkinson disease in the elderly adult. Mo Med 2013;110:406-10
3. Boeve BF. Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol 2013;12:469-82
4. Kaufmann H, Goldstein DS. Autonomic dysfunction in Parkinson disease. Handb Clin Neurol 2013;117:259-78
5. Maass A, Reichmann H. Sleep and non-motor symptoms in Parkinson's disease. J Neural Transm 2013;120:565-9
6. Olanow CW, Stocchi F, Lang A. Parkinson's disease: non-motor and non-dopaminergic features. Wiley-Blackwell; Hoboken, NJ, USA: 2011
7. Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-34
8. Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord 2012;27:8-30
9. Olanow CW. The pathogenesis of cell death in Parkinson's disease. Mov Disord 2007;17:S335-42
10. Suchowersky O, Gronseth G, Perlmutter J, et al. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:976-82
11. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1993;328:176-83
12. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-61
13. Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord 2002;8:271-6
14. Shults C W, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-50
15. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101
16. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-6
17. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-08
18. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66:664-71
19. Tilley BC, Galpern WR. Screening potential therapies: lessons learned from new paradigms used in Parkinson disease. Stroke 2007;2 Suppl):800-3
20. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68:20-8
21. Olanow C W, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-78
22. Stocchi F and Olanow CW. Obstacles to the development of a neuroprotective therapy for Parkinson's disease. Mov Disord 2013;28:3-7
23. Dorszewska J, Prendecki M, Lianeri M, Kozubski W. Molecular Effects of L-dopa Therapy in Parkinson's Disease. Curr Genomics 2014;11-17
24. Müller T, Muhlack S. Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients. Mov Disord 2011;543-6
25. Müller T, Muhlack S. Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients. J Neural Transm 2014;643-8
26. Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998;561-75
27. Schapira AH. "The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease". Mov Disord 2008;23:S515-20
28. Zesiewicz TA. Parkinson disease: the controversy of levodopa toxicity in Parkinson disease. Nat Rev Neurol 2012;8:8-10
29. Müller T, Jugel C, Muhlack S, Klostermann F. Methyl group-donating vitamins elevate 3-O-methyldopa in patients with Parkinson disease. Clin Neuropharmacol 2013;52-4
30. Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 2013;374-84
31. Lima MM, Targa AD, Noseda AC, et al. Does Parkinson's disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments? CNS Neurol Disord Drug Targets 2014;418-28
32. Santiago JA, Potashkin JA. Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol Med 2013;176-86
33. Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson's disease. Diabetes Care 2011;910-15
34. Cereda E, Barichella M, Cassani E, et al. Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology 2012;1507-11
35. Santiago JA, Potashkin JA. System-based approaches to decode the molecular links in Parkinson's disease and diabetes. Neurobiol Dis 2014. [Epub ahead of print]
36. Shin JH, Ko HS, Kang H, et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011;144:689-702
37. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003;34(3):267-73
38. Zheng B, Liao Z, Locascio JJ, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010;2:52ra73
39. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med (Berl) 2004;82:510-29
40. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest 2013;123:2730-6
41. Chaturvedi RK, Beal MF. PPAR: a therapeutic target in Parkinson's disease. J Neurochem 2008;106:506-18
42. Nicolakakis N, Aboulkassim T, Ongali B, et al. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 2008;28:9287-96
43. Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006;6:246-54
44. Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-a-b/d and -c in the adult rat. Endocrinology 1996;137:354-66
45. Mukherjee R, Jow L, Croston GE, Paterniti JR. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARc2 versus PPARc1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997;272:8071-6
46. Varga T, Czimmerer Z, Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta 2011;1812:1007-22
47. Cimini A, Benedetti E, Cristiano L, et al. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors RXRs in rat cortical neurons. Neuroscience 2005;130:325-37
48. Moreno S, Farioli-Vecchioli S, Cerù MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid receptors in the adult rat CNS. Neuroscience 2004;123:131-45
49. Carta AR, Frau L, Pisanu A, et al. Rosiglitazone decreases peroxisome proliferator receptor-c levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. Neuroscience 2011;194:250-61
50. Sarruf DA, Yu F, Nguyen HT, et al. Expression of peroxisome proliferator-activated receptor-c in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 2009;150:707-12
51. Swanson C, Emborg M. Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates. Neurol Res 2014;36(7):634-46
52. Bernardo A, Minghetti L. Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists. PPAR Res 2008;2008:864140
53. Ricote M, Glass CK. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 2007;1771:926-35
54. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649-88
55. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007;447:1116-20
56. Pascual G, Sullivan AL, Ogawa S, et al. Anti-inflammatory and antidiabetic roles of PPARgamma. Novartis Found Symp 2007;286:183-96
57. Satoh N, Shimatsu A, Himeno A, et al. Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients: effect of pioglitazone. Diabetes Care 2010;33:e7
58. Carta AR. PPAR-gamma: therapeutic prospects in Parkinson's disease. Curr Drug Targets 2013;14:743-51
59. Heneka MT, Landreth GE, Hüll M. Drug insight: effects mediated by peroxisome proliferator-activated receptor-c in CNS disorders. Nat Clin Pract Neurol 2007;3:496-504
60. Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 2008;13:1813-26
61. Breidert T, Callebert J, Heneka MT, et al. Protective action of the peroxisome proliferatoractivated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002;82:615-24
62. Dehmer T, Heneka MT, Sastre M, et al. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 2004;88:494-01
63. Hunter RL, Choi DY, Ross SA, Bing G. Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci Lett 2008;432:198-201
64. Kumar P, Kaundal RK, More S, Sharma SS. Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. Behav Brain Res 2009;197:398-403
65. Swanson CR, Joers V, Bondarenko V, et al. The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation 2011;8:91
66. Swanson CR, Du E, Johnson DA, et al. Neuroprotective properties of a novel non-thiazoledinedione partial PPAR-gamma agonist against MPTP. PPAR Res 2013;2013:582809
67. Schintu N, Frau L, Ibba M, et al. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci 2009;29:954-63
68. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
69. Kahn SE, Zinman B, Lachin JM, Haffner SM, et al. Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-51
70. Home PD, Pocock SJ, Beck-Nielsen H, et al. RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35
71. US FDA. Available from: www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM226959.pdf
72. US FDA. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm
73. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
74. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8
75. Barbalat Y, Dombrovskiy VY, Weiss RE. Association between pioglitazone and urothelial bladder cancer. Urology 2012;80:1-4
76. Bosetti C, Rosato V, Buniato D, et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 2013;18:148-56
77. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012;184:E675-83
78. Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med 2013;30:1026-32
79. Kostapanos MS, Elisaf MS, Mikhailidis DP. Pioglitazone and cancer: angel or demon? Curr Pharm Des 2013;19:4913-29
80. Monami M, Dicembrini I, Mannucci E. Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials. Acta Diabetol 2014;51:91-101
81. Turner RM, Kwok CS, Chen-Turner C, et al. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol 2014;78(2):258-73
82. Zhu Z, Shen Z, Lu Y, et al. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2012;98:159-63
83. Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012;344:e3645
84. Mamtani R, Haynes K, Bilker WB, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst 2012;104:1411-21
85. Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012;55:1953-62
86. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34:916-22
87. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012;35:278-80
88. Vallarino C, Perez A, Fusco G, et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig 2013;33:621-31
89. Wei L, MacDonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 2013;75:254-9
90. Cohen SM. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci 2005;87:322-7
91. Suzuki S, Arnold LL, Pennington KL, et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci 2010;113:349-57
92. Tseng CH, Tseng FH. Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2012;30:368-402
93. Varley CL, Stahlschmidt J, Smith B, et al. Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. Am J Pathol 2004;164:1789-98
94. Pioglitazone in Early Parkinson's Disease. 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01280123
95. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson's Disease. J Parkinsons Dis 2014;4(3):337-44